<DOC>
	<DOCNO>NCT01272791</DOCNO>
	<brief_summary>The primary objective study compare overall survival patient stage IV pancreatic cancer treat gemcitabine alone gemcitabine bavituximab .</brief_summary>
	<brief_title>Trial Gemcitabine With Without Bavituximab Patients With Previously Untreated Stage IV Pancreatic Cancer</brief_title>
	<detailed_description>This prospective , randomize , open-label , multicenter , phase 2 study gemcitabine without bavituximab patient previously untreated stage IV pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent obtain . Adults 18 year age old life expectancy least 3 month . Patients histologically cytologically document stage IV ductal adenocarcinoma pancreas . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Adequate hematologic function ( ANC ≥ 1,500 cells/µL ; hemoglobin ≥ 9 g/dL , platelet ≥ 100,000/µL ) . Adequate renal function ( serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 60 mL/min ) . Adequate hepatic function ( bilirubin ≤ 1.5 x ULN , ALT ≤ 3 x ULN , AST ≤ 3 x ULN ) ; ALT AST may &lt; 5 x ULN due liver metastasis . PT/INR ≤ 1.5 × ULN . aPTT ≤ 1.5 × ULN . Female patient must negative urine serum pregnancy test screening ( pregnancy test require patient bilateral oophorectomy and/or hysterectomy patient &gt; 1 year postmenopausal ) . All patient reproductive potential must agree use approved form contraception ( determined investigator ) . Neuroendocrine tumor ( carcinoid , islet cell cancer ) pancreas . NYHA Class III IV , cardiac function , myocardial infarction within 6 month prior Day 1 , unstable arrhythmia symptomatic peripheral arterial vascular disease . Known brain , leptomeningeal epidural metastasis . Radiation therapy within 7 day Study Day 1 , lack recovery previous therapeutic radiation , plan radiation therapy study period . Previously receive systemic treatment pancreatic cancer , include prior neoadjuvant adjuvant chemotherapy low stage disease . Previously malignancy , except adequately treat nonmelanoma skin cancer , situ cancer , cancer subject diseasefree least 5 year . Severe chronic obstructive pulmonary disease hypoxemia . Major surgery , diagnostic surgery , within 4 week prior Day 1 , without complete recovery . Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy . Ongoing therapy oral parenteral anticoagulant ; patient lowdose anticoagulant maintain patency line eligible . Venous thromboembolic event ( e.g . deep vein thrombosis pulmonary embolism ) within 6 month screen . QTC interval &gt; 470 m screening . Long QT syndrome family history sudden cardiac death young family member . Subjects participate investigational drug device study within 28 day prior study entry . Known active infection HIV , hepatitis B , hepatitis C. Females pregnant breastfeeding . Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study . Unwillingness inability comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>metastatic stage IV pancreatic cancer</keyword>
</DOC>